HOLX nears its 52-week high on diagnostics growth and AI adoption, while tariffs and challenges in China continue to pose risks.

Hologic HOLX is set to release third-quarter fiscal 2025 results on July 30, after the closing bell. The Zacks Consensus Estimate for third-quarter earnings per share (EPS) suggests a 0.9% decrease ...

At a glance, Hologic HOLX appears to be attractively priced, as reflected by its Value Score of B. The Marlborough, MA-based company, which specializes in women’s health products, is currently trading ...

Hologic (HOLX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

I am initiating a Buy rating on Hologic, Inc. with a fair value of $81, as current risks are priced in. Hologic's strong diagnostic portfolio, recurring consumables revenue, and expanding assay menu ...

Hologic (HOLX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

Hologic Inc (NASDAQ:HOLX) posted Q3 adjusted EPS of $0.93, down from $0.95 a year ago and beating the consensus of $0.88. Revenue of $984.4 million decreased 1.8% Y/Y (down 1.6% on constant currency), ...

Shares of Hologic Inc. HOLX dropped more than 3% in the aftermarket Monday after the medical technology company topped Wall Street estimates for its fiscal third quarter and tweaked its guidance for ...

In the fourth quarter of fiscal 2025, Diagnostics revenues increased 1.5% in constant currency (CC), driven by higher core ...

The valuation also compares favorably to peers QIAGEN QGEN and Abbott ABT, which have a P/S of 3.30X and 2.50X, respectively. Still, the stock trades at a premium to the broader Medical sector’s ...